ArticleCurrent microbiology2022
Does Bacillus velezensis Strain RP137 from the Persian Gulf Really Produce an Aminoglycoside?
Article in Current microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Update of the list of qualified presumption of safety (QPS) recommended microbiological agents intentionally added to food or feed as notified to EFSA 17: suitability of taxonomic units notified to EFSA until September 2022.EFSA journal. European Food Safety Authority · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It has recently been published that an aminoglycoside, S‑137‑R, is produced by a newly isolated Bacillus velezensis strain RP137 from the Persian Gulf (Pournejati et al. in Curr Microbiol 76:1028-1037, 2019). However, the analytical data presented by the authors do not allow for a structure elucidation. The data does not even prove that the authors studied an individual compound in terms of analytics and biological activity. The purity of the substance S-137-R is severely doubted because the analytics is inadequate. The molecular mass cannot be assigned on the basis of the published mass spectrum. Fundamental 2D experiments as well as proper data analysis of the presented 1D data are missing. There is no adequate comparison with other data of structurally characterized and confirmed aminoglycosides possible. In conclusion, an assignment of an aminoglycoside is scientifically not justified. Consequently, the EFSA's QPS listing requirement to prove the "absence of aminoglycoside production ability" should be no obligation anymore to approve a B. velezensis species as probiotic.
Indexed as
Identifiers
35091820What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.